The overall purpose of these guidelines is to help physicians manage adults with tuberculosis (TB)/human immunodeficiency virus (HIV) co-infection. Recommendations for the treatment of TB in adults living with HIV are similar to those in HIV-negative adults. Of note, the term ‘HIV’ refers to HIV-1 throughout these guidelines.
The 2021 interim update to the 2018 BHIVA guidelines for the management of tuberculosis in adults living with HIV was published to ensure that guidance reflects new research data, including data from the World Health Organization, on management of drug-resistant TB. All changes are highlighted.
The comments received during the public consultation can be found below. All comments were reviewed and discussed and the guidelines amended where appropriate.
Please note: The non-technical summary is less detailed than the full guideline and if you are reading this because it is relevant to your own healthcare, please do discuss any concerns or questions with your healthcare professionals.
Margherita Bracchi, Chelsea and Westminster Hospital, NHS Foundation Trust
Clare van Halsema, North Manchester General Hospital, Liverpool School of Tropical Medicine
Frank Post, King's College Hospital NHS Foundation Trust
Funmi Awosusi, Barts Health NHS Trust, HIVPA
Alison Barbour, Croydon Health Services NHS Trust
Steve Bradley, UK Community Advisory Board
Katherine Coyne, Homerton University Hospital
Esther Dixon-Williams, UK Community Advisory Board
Andrew Freedman, Cardiff University School of Medicine
Pauline Jelliman, Royal Liverpool and Broadgreen University Hospital Trust, NHIVNA
Saye Khoo, University of Liverpool
Clifford Leen, NHS Lothian
Marc Lipman, Royal Free London NHS Foundation Trust
Sebastian Lucas, Guy's and St Thomas' Hospital NHS Foundation Trust
Rob Miller, Mortimer Market Centre
Kay Seden, University of Liverpool
Anton Pozniak (Chair), Chelsea and Westminster Hospital NHS Foundation Trust
We aim to revise these guidelines in 2021. In the meantime, the writing group will confer at least annually to consider new information from high-quality studies and will issue revisions or updates should clinically important and relevant data become available.